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Financial dLymphocytes in Umbilical Cord Blood in Comparison
with Adult Peripheral Blood
Szonja Kollar,1 Noemi Sandor,2 Attila Molvarec,3 Balazs Stenczer,3 Janos Rigo Jr.,2
Tivadar Tulassay,1 Barna Vasarhelyi,4 Gergely Toldi1Umbilical cord blood (UCB) is a promising alternative for the treatment of hematological malignancies. The
lower immune reactivity of UCB lymphocytes is a well-known phenomenon; however, immune tolerance
mechanisms are not fully elucidated. Galectin-1 has strong immunosuppressive properties and plays a key
role in the regulation of immune reactivity. We aimed to determine the properties of intracellular
galectin-1 (Gal-1)-producing cells within CD3, CD4, CD8, regulatory T (Treg), and natural killer (NK) cells
in UCB compared to adult peripheral blood (APB).We took peripheral blood samples from 22 healthy adults
and cord blood samples from 19 healthy, term neonates. Intracellular Gal-1 expression was determined by
flow cytometry in the above subsets. Furthermore, we assessed the prevalence of naive and memory T cells
that play a role in the regulation of immune reactivity. We also performed functional analyses to assess the
effect of exogenous Gal-1 on the rate of proliferation of T lymphocytes isolated from APB and UCB. The
prevalence of intracellular Gal-1-expressing CD3, CD4, CD8, Treg and NK lymphocytes was lower in
UCB than in APB. However, their capability to produce Gal-1 reaches the level seen in adults. The prevalence
of naive cells was higher, whereas that of central and effector memory T cells was lower in UCB compared
with APB. Lower Gal-1-producing cell proportion might be due to the naivety of neonatal lymphocytes, as
indicated by the positive correlation detected between the number of CD3 lymphocytes expressing intra-
cellular Gal-1 and the prevalence of memory T cells. The intracellular expression of Gal-1 may be down-
regulated in neonatal lymphocytes due to the already reduced immune reactivity of UCB. In contrast with
previous findings, our results indicate that the administration of exogenous Gal-1 failed to decrease the
rate of proliferation in T lymphocytes isolated from either APB or UCB. This suggests that Gal-1-
expressing lymphocytes are unlikely to play a major role in mitigating the immune reactivity of UCB.
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Besides bone marrow (BM) and peripheral blood,
umbilical cord blood (UCB) is 1 of the 3 sources for
hematopoietic stem cells and progenitor cells used
for the treatment of hematological malignancies [1].
UCB is a promising alternative for hematopoietic
stem cell transplantation, because a reduced risk of
graft-versus-host disease (GVHD) has been suggested
with UCB compared to BM. Furthermore, HLA-
incompatibility is better tolerated by patients when
UCB is used for transplantation [2].
To date, over 20 years have passed since the first
cord blood transplantation; however, the immunolog-
ical properties of UCB that account for the reduced in-
cidence and severity of GVHD are still not fully1First Department of Pediatrics, Semmelweis University,
est, Hungary; 2Department of Immunology, E€otv€os
d University, Budapest, Hungary; 3First Department of
trics and Gynecology, Semmelweis University, Budapest,
ary; and 4Department of Laboratory Medicine, Semmel-
niversity, Budapest, Hungary.
isclosure: See Acknowledgment on page 1612.understood. There are a number of important lympho-
cyte subsets that play a role in the regulation of im-
mune reactivity, such as regulatory T cells (Tregs),
naive, and memory T cells. Cytotoxic T and natural
killer (NK) cells have been implicated as the most im-
portant effector cell types in the pathogenesis of
GVHD [3]. Other studies described that CD41
CD25high Treg cells capable of suppressing alloge-
neic immune responses may ameliorate GVHD [4,5].
Several other aspects have been suggested to be of
importance in the lower immune reactivity of UCB
lymphocytes. These include altered cytokine
production patterns [3,6-8] and calcium influx
kinetics in neonatal lymphocytes [9]. Neonatal Th1
and cytotoxic T cells are hyporesponsive compared
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and for the improvement of transplantation outcomes,
it is important to investigate if other factors may also
contribute to the reduced immune reactivity of UCB
compared with adult peripheral blood (APB).
Galectin-1 (Gal-1) plays a key role in the regula-
tion of inflammatory responses and immune tolerance
with strong immunosuppressive properties [11]. It
supports the survival of naive T cells without promot-
ing cell proliferation [12] and also has antiproliferative
effects on activated T cells [13,14]. Gal-1 induces apo-
ptosis of CD8 and Th1 cells [15]. However, Th2 cells
are protected from Gal-1-mediated cell death [15].
Gal-1 also suppresses the secretion of the proinflam-
matory cytokine IL-2 [16] and favors the secretion of
the anti-inflammatory IL-10 [17]. Thus, it skews the
Th1/Th2 balance toward the production of Th2-
type cytokines [18]. Gal-1 is also regarded as a very
plausible effector molecule for the function of CD41
CD25high regulatory T cells [19].
We hypothesized that Gal-1 is expressed at higher
amounts in neonatal lymphocytes contributing to the
lower level of immune reactivity of UCB compared
with APB. In this study, we aimed to determine the
properties of intracellular Gal-1-expressing (Gal-11)
cells within major lymphocyte subsets (CD3, CD4,
CD8, Treg, and NK cells) in UCB compared to APB.METHODS
Peripheral blood sampleswere taken from22healthy
adults (11 women and 11 men; age, 27 years [25-28
years];median [interquartile range]) and cordblood sam-
ples from 19 healthy, term neonates (10 girls and 9 boys;
gestational age, 39 weeks [38-40 weeks]; median [inter-
quartile range]; birth weight, 3500 grams [3305-3805
grams]; median [interquartile range]). Informed consent
was obtained from all subjects or, in the case of neonates,
parents of subjects, and our study was reviewed and
approved by an independent ethical committee of the in-
stitution.The studywas adhered to the tenets of themost
recent revision of the Declaration of Helsinki.
Peripheral blood mononuclear cells and cord
blood mononuclear cells were separated by a standard
density gradient centrifugation (Ficoll Paque; Amer-
sham Biosciences AB, Uppsala, Sweden; 25 minutes,
400 g, 22C) from freshly drawn blood collected in
lithium heparin-treated tubes (BD Biosciences, San
Jose, CA). This cell suspension was washed twice in
PBS and then divided into 2 portions.
One portion of the cells was stained with allophy-
cocyanin (APC)-Cy7-labeled anti-human CD4,
fluorescein isothiocyanate (FITC)-labeled anti-human
CD45RA, and phycoerythrin (PE)-labeled anti-hu-
man CCR7mouse monoclonal antibodies (BD Biosci-
ences) for 30 minutes at room temperature in the dark
and then washed in PBS.Another portion of the cells was stained with APC-
labeled anti-human CD3, peridinin chlorophyll
protein-labeled anti-human CD56, PE-Cy7-labeled
anti (PerCP)-human CD4, APC-Cy7-labeled anti-
human CD8, and FITC-labeled anti-human CD25
mouse monoclonal antibodies (BD Biosciences) for
30 minutes at room temperature in dark and then
washed. Five hundred ml of 1X FACS Permeabilizing
Solution (BD Biosciences) was added, and the mixture
was incubated for 10 minutes at room temperature in
dark. After washing with PBS, the permeabilized cells
were treated with in-house biotinylated (Biotin Label-
ing Kit-NH2; Dojindo Laboratories, Tabaru, Kuma-
moto, Japan) anti-human Gal-1 mouse monoclonal
antibody (Vector Laboratories, Burlingame, CA) for
30 minutes at room temperature in dark. In-house
biotin-conjugated (Dojindo Laboratories), isotype-
matched mouse IgG1 antibody (R&D Systems,
Minneapolis, MN) was used as a control for detecting
nonspecific binding. After washing off the unbound bi-
otinylated Abs, cells were stained with PE-labeled
streptavidin (BD Biosciences) for 15 minutes at room
temperature in dark.
After washing, cells were analyzed on a BDFACSA-
ria flow cytometer (BDBiosciences). A total of 200,000
cells were recorded. The population of viable lympho-
cytes was gated from peripheral blood mononuclear
cells according to Forward Scatter Characteristics
and Side Scatter Characteristics. The Treg cells were
defined as CD41 CD25high cells. Naive cells were
defined as CD41 CD45RA1 CCR71 cells, central
memory T cells were defined as CD41 CD45RA2
CCR71, whereas CD41 CD45RA2 CCR72 cells
were regarded as effector memory T cells. Gal-11
cells were gated based on isotype control recordings
to determine unspecific Ab binding.
For functional analyses, CD31 T cells were iso-
lated from APB or UCB using magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). The
5  105 T cells were cultivated either in the presence
or absence of 1 mg/mL ConA (Sigma-Aldrich, St.
Louis, MO) in CellGro serum free medium (CellGe-
nix, Freiburg, Germany). For testing whether exoge-
nously added Gal-1 modulates the cells’ proliferating
capacity, 5 mM recombinant human Gal-1 (Sino Bio-
logical, Beijing, China) was added simultaneously
with ConA treatment. Samples were run in quadrupli-
cate. After 3 days of culture, 1 mCi 3H-thymidine was
added (Perkin-Elmer, Waltham, MA). 3H-thymidine
incorporation (CPM) was measured 18 hours later
on Wallac liquid scintillation beta counter.
Data are expressed as median (interquartile range).
Comparisons between the 2 sample populations were
made withMann-Whitney tests. For correlation analy-
ses, the Spearman test was applied. In case of functional
analyses, data are given as mean 6 SD. P values
\ .05 were considered significant. The sample size
Table 1. Prevalence of the Investigated Lymphocyte Subsets in APB and UCB
Lymphocyte Subset APB (n 5 22) UCB (n 5 19) P Value
NK cells/lymphocytes (CD32 CD56+) 9.93 (6.79-14.50) 6.08 (4.57-9.14) .006
T cells/lymphocytes (CD3+ CD562) 63.50 (60.90-66.70) 66.10 (55.80-67.70) NS
CD4 cells/lymphocytes (CD4+ CD82) 49.10 (42.40-50.60) 54.90 (42.20-57.50) NS
CD8 cells/lymphocytes (CD42 CD8+) 19.20 (12.40-23.70) 14.20 (11.00-18.30) .04
Treg cells/CD4 cells (CD4+ CD25high) 6.19 (5.55-7.80) 4.64 (3.64-6.41) .03
Naive cells/CD4 cells (CD4+ CD45RA+ CCR7+) 47.40 (39.10-54.20) 54.10 (49.70-57.00) .03
Central memory T cells/CD4 cells (CD4+ CD45RA2 CCR7+) 25.90 (15.60-29.90) 13.80 (12.70-15.70) .009
Effector memory T cells/CD4 cells (CD4+ CD45RA2CCR72) 16.80 (15.80-22.60) 12.80 (10.40-14.00) .0004
APB indicates adult peripheral blood; UCB, umbilical cord blood; NK, natural killer; NS, not significant; Treg, regulatory T cell.
Data are presented as median (interquartile range).
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size to detect differences between intracellular Gal-1
expressions in the sample groups. Statistics were
calculated using the R software (R Development Core
Team, R Foundation for Statistical Computing,
Vienna, Austria).RESULTS
First, we assessed the differences between the prev-
alence of significant lymphocyte subsets in cord blood
compared toAPB.Results are shown inTable 1.Briefly,
the prevalence of NK, CD8, and Treg (CD41
CD25high) cells was lower in UCB compared with
APB. The prevalence of naive cells was higher, whereas
that of central and effectormemoryT cells was lower in
UCB compared with APB. We also assessed the mean
fluorescence intensity of the CD25 marker on Tregs.
This was found to be higher in UCB than in APB
Treg cells (261 arbitrary unit [235-335] versus 212
arbitrary unit [194-247]; P5 .02).
We investigated the prevalence of intracellular
Gal-11 CD3, CD4, CD8, Treg, and NK lympho-
cytes. The prevalence of all these cell populations
was lower in UCB than in ABP, as shown in
Figure 1 (CD3 cells: 6.58 [3.41-7.40] % versus 9.03
[5.49-12.50] %; P 5 .02; CD4 cells: 5.26 [3.23-7.51]
% versus 9.47 [4.95-12.00] %; P 5 .01; CD8 cells:
5.15 [2.94-8.25] % versus 7.22 [5.59-10.00] %; P 5
.02; Treg cells: 6.12 [2.05-7.26] % versus 8.69
[5.23-10.70] %; P 5 .03; NK cells: 6.91 [2.57-9.68]
% versus 9.16 [5.63-12.90] %; P 5 .05). We also de-
termined the mean fluorescence intensity of intracel-
lular Gal-1 in the above major lymphocyte subsets
among Gal-11 cells. No difference was detected in
this regard between UCB and APB (Table 2). The
highest mean fluorescence intensity of intracellular
Gal-1 was detected in the Treg subset among Gal-
11 cells.
We also analyzed if there was a correlation be-
tween the proportion of intracellular Gal-11 lympho-
cytes and the prevalence of the other investigated cell
subsets. Interestingly, we found a positive correlationbetween the number of CD3 lymphocytes expressing
intracellular Gal-1 and the prevalence of CD45RA-
cells (ie, central and effector memory T cells) in
UCB (r 5 0.49 and 0.40, respectively; P 5 .03 and
.04, respectively). A positive correlation was also
detected between the proportion of intracellular Gal-
1-expressing CD3, CD4, CD8, Treg, and NK lym-
phocytes and the prevalence of NK cells in both
UCB and APB. The expression of intracellular Gal-1
in the investigated major lymphocyte subsets was not
related to the birth weight or the gestational age
of newborns, indicating that these factors do not
influence Gal-1 expression in UCB, at least in the
case of term newborns without intrauterine growth
retardation.
Our functional analysis showed that unactivated T
cells isolated from APB proliferated to a higher extent
than those isolated from UCB (2394 6 376 versus
1266 6 24 CPM 6 SD; P\ .01; Figure 2A). Upon
polyclonal activation with ConA, this difference was
even more considerable (20,716 6 1450 versus 11,658
6 5590 CPM 6 SD; P \ .05; Figure 2A). The
addition of recombinant human Gal-1 to cell cultures
failed to decrease the rate of proliferation in T lympho-
cytes isolated from either APB or UCB (110 6 5 and
102 6 8.6% activation compared with ConA-treated
control without Gal-1 6 SD; P . .05 for both;
Figure 2B).DISCUSSION
Previous studies have demonstrated a number of
aspects contributing to the reduced risk of GVHD as-
sociated with UCB transplants. However, the role of
an important regulator of immune tolerance, Gal-1,
has not yet been investigated in UCB. Therefore, we
determined its intracellular expression in major lym-
phocyte subsets contributing to GVHD in UCB com-
pared with APB.
Interestingly, in contrast with our hypothesis and
the well-known immunosuppressive effect of Gal-1,
we found that the prevalence of Gal-1-expressing
CD3, CD4, CD8, Treg, and NK lymphocytes are
Figure 1. Boxplots representing the prevalence of intracellular galectin-1(Gal-1)-expressing lymphocytes in adult peripheral blood (APB) and umbilical
cord blood (UCB). Horizontal line: median, box: interquartile range, whisker: range. *P \ .05 for all comparisons.
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tionmight be due to the naivety and lower level of long-
term stimulation of neonatal lymphocytes. This is
supported by the demonstrated higher prevalence of
naive, but lower prevalence of central and effector
memory T cells in comparison to APB, and the positive
correlation between the number of CD3 lymphocytes
expressing intracellular Gal-1 and the prevalence of
memory T cells. The assessment of the mean fluores-
cence intensity of Gal-1 in these cells indicates semi-
quantitatively that the amount of intracellular Gal-1 is
comparable in UCB to that in APB, and suggests that,
in contrast with cytokine producing capacity [20], the
Gal-producing capability of these cells is mature. Of
note, these findings are not directly analogous with our
analysis, because cytokine producing capacity in the
above studywasmeasuredusing adifferentmethod in re-
sponse to stimulation of cells. However, in our study, we
measured intracellularGal-1-expression in unstimulated
cells. Further studies will need to be performed to deter-
mine the ability of lymphocytes isolated from UCB to
produce Gal-1 in response to stimulation.
Based on mean fluorescence intensity data, the
highest amount of intracellular Gal-1 is expressed in
Tregs both in UCB and APB. Garın et al. [19] demon-
strated that Gal-1 is overexpressed in Tregs, and that
expression is increased after activation. Blockade ofTable 2. Mean Fluorescence Intensity Values of Intracellular
Gal-1 in the Investigated Lymphocyte Subsets among Gal-1+
Cells in APB and UCB
Lymphocyte Subset APB (n 5 22) UCB (n 5 19) P Value
T cells (CD3+ CD562) 563 (557-587) 487 (436-582) NS
CD4 cells (CD4+ CD82) 615 (580-648) 543 (454-671) NS
CD8 cells (CD42 CD8+) 585 (568-598) 519 (474-658) NS
Treg cells (CD4+ CD25high) 740 (644-1038) 579 (458-1152) NS
NK cells (CD32 CD56+) 665 (608-1074) 556 (475-1024) NS
Gal-1 indicates galectin-1; APB, adult peripheral blood; UCB, umbilical
cord blood; NS, not significant; Treg, regulatory T cell; NK, natural killer.
Data are presented as median (interquartile range).Gal-1 binding significantly reduced the inhibitory ef-
fects of human and mouse CD41 CD25high Treg
cells. Hence, their results suggest that Gal-1 is a key ef-
fector of the regulation mediated by these cells.
Our results indicate that the prevalence of CD41
CD25high Tregs is lower in UCB compared with
APB. Similar findings were reported by Ly et al. [21].
Lee et al. [22] reported that the mean fluorescent in-
tensity of CD25 expressed on UCB Treg cells was
higher than their adult counterparts. These data are
in line with our present findings.
We have demonstrated distinct alterations of the
prevalence of different lymphocyte subsets in UCB in
relation toAPB. Besides the described differences of na-
ive, central and effector memory T cells, we also ob-
served a decrease in CD8 and NK cell prevalence.
Cytotoxic T and NK cells were shown to have reduced
function when isolated fromUCB compared with APB,
and both these cell types have been implicated in the
pathogenesis of GVHD [3,10]. Thus, not only the
function but also the prevalence of these subsets seems
to be lower in UCB. Furthermore, we found that the
prevalence of NK cells was related to intracellular
Gal-1 expression of major lymphocyte subsets both in
UCB and APB. This result is of interest because in
contrast with T cells (especially the Th1 and CD8 sub-
sets [15]), Gal-1 has not yet been described to have a di-
rect effect on the number of NK cells. Further
investigation is needed to elucidate the significance of
this finding.
In contrast with expectations based on the well-
known immunosuppressive effect of Gal-1, we report
that the proportions of Gal-1-expressing CD3, CD4,
CD8, Treg, and NK lymphocytes are lower rather
than higher in UCB than in APB. However, the
amount of intracellular Gal-1 expressed by these cells
is similar to that seen in adult Gal-11 lymphocytes
based on the mean fluorescence intensity data of flow
cytometry recordings among Gal-11 cells.
Figure 2. (A) The 5  105 T cells separated from adult peripheral blood (APB) or umbilical cord blood (UCB) were cultivated for 3 days in the
presence or absence of 1 mg/mL ConA polyclonal T cell stimulator. After 3 days of culture, 3H-thymidine was added to the wells and incorporation
was measured 18 hours later. Data are given as mean CPM values 6 SD of quadruplicate samples of 3 independent donors. *P\ .05; **P\ .01.
(B) T cells from APB or UCB were separated and cultivated for 3 days in the presence of 1 mg/mL ConA and with or without 5 mM recombinant human
galectin-1 (Gal-1). After 3 days of culture, 3H-thymidine was added to the wells and incorporation was measured 18 hours later. Proliferation without
Gal-1 was regarded as 100%. Data are given as percent proliferation6 SD of ConA1Gal-1 treated samples calculated from 3 independent donors. No
statistically significant difference was detected compared with ConA treated samples without Gal-1.
1612 Biol Blood Marrow Transplant 18:1600-1613, 2012S. Kollar et al.Based on our results, it is difficult to establish the
cause for the detected differences. However, it is pos-
sible that the lower intracellular expression of Gal-1 is,
at least in part, due to the already reduced immune re-
activity of UCB. Therefore, the intracellular expres-
sion of Gal-1 is down-regulated compared with
APB. Previous experiments in mice suggested that
the administration of exogenous Gal-1 might be a pos-
sible therapeutic approach for further reducing the
immune reactivity of UCB, and hence improve the
outcome of UCB transplants [23]. However, our func-
tional analyses in human T cells isolated from ABP
and UCB do not support this assumption. The addi-
tion of recombinant human Gal-1 to cell cultures
failed to decrease the rate of proliferation in T lym-
phocytes isolated from either APB or UCB. This sug-
gests that Gal-1-expressing lymphocytes are unlikely
to play a major role in mitigating the immune reactiv-
ity of UCB.
A report by Kiss et al. [24] suggests that Gal-1
prevents transmigration of stem cells from the BM
into peripheral blood upon cyclophosphamide and
granulocyte colony-stimulating factor stimulation.
An interesting area of future work would be to see if
the levels of Gal-1 were decreased in mobilized APB
stem cells compared with UCB lymphocytes, and to
assess the factors responsible for the regulation of the
effects of Gal-1 on stem cells in comparison with lym-
phocytes.
Further studies are needed with the determination
of baseline UCB plasma Gal-1 and anti-Gal-1 auto-
antibody levels and with the detailed investigation
of the effects of exogenous Gal-1 on the immune
reactivity of UCB and on the outcome of GVHD oc-
currence in UCB transplants.ACKNOWLEDGMENT
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